Over the last few weeks, I’ve been adding extra items to my formulary, making sure all my boxes are ticked when it comes to women’s health. Something I was especially keen to explore was whether there were probiotic strains or formulations shown to be effective at reducing pain or symptoms of conditions like PCOS/PMOS, adenomyosis, endometriosis - or even just period pain. It turns out there is a little bit of research, and one paper in particular got me excited.
In 2011, a team of Japanese researchers ran a proper randomised, double-blind, placebo-controlled trial on a probiotic strain and found it meaningfully reduced menstrual pain. No side effects. Measurable results on two separate pain scales. The kind of clean result that, in most areas of medicine, gets you a product launch within a few years.
And yet, it's been fifteen years since the paper was published. You cannot buy it.
I want to tell you more about this, because it's not really a story about a probiotic.
It's a story about what happens to women's health research after the data comes in — and why "the evidence exists" and "the product exists" are two completely different sentences.
The study
The strain is called Lactobacillus gasseri OLL2809, and the research came out of Meiji — yes, the same Meiji that makes dairy products and chocolate in Japan, which also happens to run a serious pharmaceutical and microbiology research division. Led by a researcher named Itoh, the team gave women with endometriosis a tablet containing heat-killed OLL2809, or a placebo, once a day for twelve weeks. Nobody knew which group they were in. Afterwards, the women rated their pain on two validated scales — one for pain intensity, one for dysmenorrhea specifically — and the group taking the probiotic showed significant improvement on both, with no adverse effects reported.
I want to be precise about what this does and doesn't tell us, because I think the precision is actually the interesting part. This was one trial, with a modest sample (around 30 women per group), specifically in women with endometriosis rather than period pain in general. It hasn't been widely replicated. So the honest version of this isn't "this probiotic cures period pain" — it's "a specific, heat-killed bacterial strain was shown, in a well-designed trial, to meaningfully reduce pain in a population of women whose pain is notoriously hard to treat." That's still remarkable. It's just not the whole story yet, and I don't want to oversell a single paper the way so much wellness content does.
So what happened to it?
Here's where it gets interesting. OLL2809 didn't disappear. It didn't fail some follow-up safety check or get quietly buried in a filing cabinet. It kept being studied — just not for period pain.
The reason why the strain was studied in the first place is likely because it sat inside a much larger network of research that Meiji was conducting on OLL2809 as an immune-modulating strain. Meiji’s team had already been characterising it for its ability to stimulate interleukin-12 production and activate natural killer cells. Women with endometriosis tend to show reduced NK cell activity in the peritoneal cavity, which allows ectopic endometrial tissue to evade immune clearance and keep growing where it shouldn’t. The team investigating it had a real mechanistic rationale for investigating it for endometriosis.
The same strain went on to be investigated for Japanese cedar pollen allergy, where heat-killed OLL2809 reduced allergic symptoms in people with high pollen sensitivity. It was studied for its effect on immune cells directly — how it modulates the balance between Th1 and Th2 immune responses and suppresses T cell proliferation, and separately, how it activates natural killer cells to suppress the development of endometrial tissue in an animal model. Meiji's own research pipeline kept going. They just took this strain and pointed it at allergies and general immune modulation instead.
And yet the trial that showed it reduced menstrual pain — arguably the more commercially obvious use, given how many women would pay for literally anything that worked — never resulted in a product on a shelf.
I don't know Meiji's internal reasoning, and I’ll be honest: I'm speculating here rather than reporting fact. But I don't think you need an internal memo to see the pattern. Hay fever is a condition everyone, including men, including regulators, including investors, immediately understands as real and worth treating. Period pain is a condition half the population has lived with quietly, has been told is normal, has had doctors shrug at for decades.
One of those gets a straightforward path to market.
The other requires someone to decide that women's pain is worth building a supply chain for.
Why this matters beyond one probiotic
This is the key point I actually want you to sit with, more than the specific strain name. The reason why this product never went to market is likely more than an economic story.
Women control an enormous share of global health spending and consistently outspend men on healthcare per capita. This was never a case of the market being too small or too poor to bother with.
What's thin isn't demand. It's legitimacy. Research into women's reproductive health still receives a strikingly small share of total R&D and venture funding, even though the economic case for closing that gap is strong. The money to reward this kind of research exists. It's the decision to go after it that's been missing. And that decision has a lot more to do with whose pain gets taken seriously than with whether anyone would pay for the solution.
Endometriosis itself is the clearest example of this. It affects roughly one in ten women of reproductive age — around 190 million people worldwide — and a recent systematic review and meta-analysis found diagnostic delays still commonly run from four to eleven years from symptom onset to confirmed diagnosis. The research gap isn't really a knowledge gap. We know enough to run proper trials, as this one shows. The gap is in what happens after the data exists, whose pain gets taken seriously enough to turn a finding into something you can buy at a pharmacy.
I think this is worth naming clearly, because it changes how you read "there's no evidence for that" when it comes to women's health. Sometimes that sentence means the evidence genuinely doesn't exist, because in all honesty, very few researchers have chosen to look at women as little more than small versions of men for hundreds of years. And sometimes it means the evidence exists, sat in a journal for over a decade, and nobody with capital decided your pain was a priority worth funding a product launch for.
What you can actually do with this
I'm not going to tell you to go track down heat-killed L. gasseri OLL2809, because you can't — it was never formulated into a consumer product, as far as I can find. That's slightly maddening to write, but I'd rather tell you the truth than send you on a wild goose chase.
What I think this is actually useful for is recalibrating how much weight you put on "well, there's no product for that" as a signal of anything. It isn't necessarily a signal about efficacy. More often it's a signal about where funding has historically flowed, which tends to follow symptoms that are visible, dramatic, or affect men too — and away from the quieter, cyclical, "just take some paracetamol" pain that half the population has been managing alone for generations.
Probiotics more broadly do have a genuine, evolving evidence base for menstrual and gynaecological symptoms — this isn't the only strain, and research in this space (gut-microbiome-hormone interactions, vaginal microbiome research, other Lactobacillus strains in menstrual health trials) has continued since 2011. If you're exploring probiotic support for period pain or hormonal symptoms, that's a conversation worth having with a practitioner who can match the right strain and dose to what's actually going on for you, rather than hoping a generic multi-strain capsule off a supermarket shelf happens to contain something relevant. Most commercial probiotics weren't formulated with dysmenorrhea in mind at all, so "it's a probiotic" tells you almost nothing about whether it will do anything for period pain specifically.
And more broadly — if you've ever been told your pain is "just part of being a woman," I'd ask you to hold that lightly. Sometimes the research to take it seriously already exists. It's just that nobody decided yet that you were worth building something for.
If anything in this resonates with your own experience of being told your pain was normal when it clearly wasn't, it's worth taking seriously rather than managing around it indefinitely.
Want some help working out what's actually driving your period pain or hormonal symptoms, rather than just managing them? You can book a free discovery call to see if working together might be a good fit.